Nöroblastom

Year 2006, Volume: 4 Issue: 1, 128 - 132, 01.04.2006

Metin Demirkaya Betül Sevinir

Abstract

Nöroblastom; adrenal medulla ve sempatik ganglionlarda görülen ve ilkel nöral krest hücrelerinden orijin alan bir tümördür. Diğer tümörlerle karşılaştırıldığında; primer tümörün, metastatik hastalığın ve paraneoplastik sendromların farklı klinik presentasyonu olabilir. Spontan regresyonlar, benign hastalı- ğa farklılaşma, ileri yaştaki çocuklarda oldukça malign seyretmesi, nöroblastomun farklı davranışlarına örnek olarak verilebilir.

References

• 1. Gurney JG, Davis S, Severson RK, Fang JY, Ross JA, Robison LL. Trends in cancer incidence among children in the U.S. Cancer 1996; 78:532-41.
• 2. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 1997; 19:428-32.
• 3. Olshan AF, Smith J, Cook MN, et al. Hormone and fertility drug use and the risk of neuroblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. Am J Epidemiol 1999; 150:930-8.
• 4. Olshan AF, De Roos AJ, Teschke K, et al. Neuroblastoma and parental occupation. Cancer Causes Control 1999; 10:539-49.
• 5. Knudson AG Jr, Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet 1972; 24:514-32.
• 6. Maris JM, Weiss MJ, Mosse Y, et al. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res 2002; 62:6651-8.
• 7. Kushner BH, Gilbert F, Helson L. Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer 1986; 57(9):1887- 93.
• 8. Verloes A, Elmer C, Lacombe D, et al. Ondine-Hirschsprung syndrome (Haddad syndrome). Further delineation in two cases and review of the literature. Eur J Pediatr 1993; 152:75-7.
• 9. Maris JM, Weiss MJ, Mosse Y, et al. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res 2002; 62:6651-8.
• 10. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313:1111-6.
• 11. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG (eds). Principles and Practice of Pediatric Oncology. 4th edition. Lippincott Williams & Wilkins; 2001:933-70.
• 12. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 1995; 24:215-21.
• 13. Gehring M, Berthold F, Edler L, Schwab M, Amler LC. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 1995; 55:5366-9.
• 14. Martinsson T, Sjoberg RM, Hedborg F, Kogner P. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res 1995; 55:5681-6.
• 15. White PS, Thompson PM, Gotoh T, et al. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 2005; 24:2684-94.
• 16. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 334:225-30.
• 17. Maris JM, Weiss MJ, Guo C, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 2000; 18(9):1888-99.
• 18. Spitz R, Hero B, Ernestus K, Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res 2003; 9:52-8.
• 19. Yano H, Chao MV. Neurotrophin receptor structure and interactions. Pharm Acta Helv. 2000; 74:253-60.
• 20. Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 2001; 11:272-80.
• 21. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328:847-54.
• 22. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994; 14:759-67.
• 23. Brodeur GM. Neuroblastoma:biological insights into a clinical enigma. Nat Rev Cancer 2003; 3:203-16.
• 24. Yamada S, Ishii E, Nakagawara A, et al. Features and outcome of advanced neuroblastoma with distant lymph node metastasis. Pediatr Hematol Oncol 1992; 9:49-56.
• 25. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999; 21:181-9.
• 26. Ho PT, Estroff JA, Kozakewich H, et al. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. Pediatrics 1993; 92:358-64.
• 27. Monsaingeon M, Perel Y, Simonnet G, Corcuff JB. Comparative values of catecholamines and metabolites for the diagnosis of neuroblastoma. Eur J Pediatr 2003; 162:397-402.
• 28. Kaplan SJ, Holbrook CT, McDaniel HG, Buntain WL, Crist WM. Vasoactive intestinal peptide secreting tumors of childhood. Am J Dis Child 1980; 134:21-4.
• 29. Qualman SJ, O'Dorisio MS, Fleshman DJ, Shimada H, O'Dorisio TM. Neuroblastoma. Correlation of neuropeptide expression in tumor tissue with other prognostic factors. Cancer 1992; 70:2005-12.
• 30. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001; 36:612-22.
• 31. Pranzatelli MR, Travelstead AL, Tate ED, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 2004; 62:1526-32.
• 32. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6:1874-81.
• 33. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-77.
• 34. Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M; EUROCARE Working Group. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 2005; 23:3742-51.
• 35. Sawada T, Kidowaki T, Sakamoto I, et al. Neuroblastoma. Mass screening for early detection and its prognosis. Cancer 1984; 53:2731-5.
• 36. Takeda T, Hatae Y, Nakadate H, et al. Japanese experience of screening. Med Pediatr Oncol 1989; 17:368-72.
• 37. Woods WG, Tuchman M, Robison LL, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996; 348:1682-7.
• 38. Schilling FH, Berthold F, Erttmann R, et al. Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results. Med Pediatr Oncol 2000; 35:701-4.
• 39. Bessho F. Comparison of the incidences of neuroblastoma for screened and unscreened cohorts. Acta Paediatr 1999; 88:404-6.
• 40. Yamamoto K, Ohta S, Ito E, et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol 2002; 20:1209-14.
• 41. Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002; 346:1041-6.